These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 33493031)

  • 1. Diamonds in the Rough: The Incredible-but-True Story of Sodium Glucose Cotransporter 2 Inhibitors in Treatment of Heart Failure.
    Kosiborod M
    Circulation; 2021 Jan; 143(4):350-353. PubMed ID: 33493031
    [No Abstract]   [Full Text] [Related]  

  • 2. Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.
    Berg DD; Wiviott SD; Scirica BM; Gurmu Y; Mosenzon O; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Johanson P; Johansson PA; Langkilde AM; Raz I; Braunwald E; Sabatine MS
    Circulation; 2019 Nov; 140(19):1569-1577. PubMed ID: 31474116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms and prediction of short-term natriuretic effect of sodium-glucose cotransporter 2 inhibitor in heart failure patients coexisting type 2 diabetes mellitus.
    Fukuoka S; Dohi K; Takeuchi T; Moriwaki K; Ishiyama M; Omori T; Fujimoto N; Ito M
    Heart Vessels; 2020 Sep; 35(9):1218-1226. PubMed ID: 32270357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
    Kato ET; Silverman MG; Mosenzon O; Zelniker TA; Cahn A; Furtado RHM; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Bonaca MP; Ruff CT; Desai AS; Goto S; Johansson PA; Gause-Nilsson I; Johanson P; Langkilde AM; Raz I; Sabatine MS; Wiviott SD
    Circulation; 2019 May; 139(22):2528-2536. PubMed ID: 30882238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to Diuretics in Heart Failure: Any Role for Empagliflozin?
    Katsiki N; Triposkiadis F
    Curr Vasc Pharmacol; 2019; 17(4):421-424. PubMed ID: 30173648
    [No Abstract]   [Full Text] [Related]  

  • 6. Empagliflozin and Major Renal Outcomes in Heart Failure.
    Packer M; Butler J; Zannad F; Pocock SJ; Filippatos G; Ferreira JP; Brueckmann M; Jamal W; Zeller C; Wanner C; Anker SD;
    N Engl J Med; 2021 Oct; 385(16):1531-1533. PubMed ID: 34449179
    [No Abstract]   [Full Text] [Related]  

  • 7. Sodium-Glucose Cotransporter-2 Inhibitors and Loop Diuretics for Heart Failure: Priming the Natriuretic and Metabolic Reserve of the Kidney.
    Grodin JL; Tang WHW
    Circulation; 2020 Sep; 142(11):1055-1058. PubMed ID: 32924569
    [No Abstract]   [Full Text] [Related]  

  • 8. Dapagliflozin (Farxiga) - a new indication for heart failure.
    Med Lett Drugs Ther; 2020 Jun; 62(1601):102-103. PubMed ID: 32724023
    [No Abstract]   [Full Text] [Related]  

  • 9. The Ethics of Conducting Clinical Trials With Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: Is Placebo Assignment Justified in Patients With Comorbid Diabetes Mellitus and Heart Failure?
    Butler J; Anker SD
    Circulation; 2017 Oct; 136(16):1459-1461. PubMed ID: 29038205
    [No Abstract]   [Full Text] [Related]  

  • 10. Sodium glucose co-transporter 2 inhibitors in heart failure therapy.
    Çavuşoğlu Y; Altay H; Cahn A; Celik A; Demir S; Kılıçaslan B; Nalbantgil S; Raz I; Temizhan A; Yıldırımtürk Ö; Yılmaz MB
    Turk Kardiyol Dern Ars; 2020 Apr; 48(3):330-354. PubMed ID: 32281958
    [No Abstract]   [Full Text] [Related]  

  • 11. Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction: The Heart and Kidney Working Better Together.
    Carnicelli AP; Mentz RJ
    Circulation; 2021 Jan; 143(4):322-325. PubMed ID: 33493029
    [No Abstract]   [Full Text] [Related]  

  • 12. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
    Patorno E; Pawar A; Franklin JM; Najafzadeh M; Déruaz-Luyet A; Brodovicz KG; Sambevski S; Bessette LG; Santiago Ortiz AJ; Kulldorff M; Schneeweiss S
    Circulation; 2019 Jun; 139(25):2822-2830. PubMed ID: 30955357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for Patients With Heart Failure in China: A New Pillar in Our Pockets, but at What Price?
    Camilli M; Ballacci F; Giordano F; Minotti G
    J Cardiovasc Pharmacol; 2024 Jan; 83(1):43-45. PubMed ID: 37815278
    [No Abstract]   [Full Text] [Related]  

  • 14. VERTIS-CV: More Evidence That Sodium Glucose Cotransporter 2 Inhibition Brings Rapid and Sustained Heart Failure Benefit.
    Zannad F; Cowie MR
    Circulation; 2020 Dec; 142(23):2216-2218. PubMed ID: 33284652
    [No Abstract]   [Full Text] [Related]  

  • 15. Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality.
    Savarese G; Sattar N; Januzzi J; Verma S; Lund LH; Fitchett D; Zeller C; George JT; Brueckmann M; Ofstad AP; Inzucchi SE; Wanner C; Zinman B; Butler J
    Circulation; 2019 Mar; 139(11):1458-1460. PubMed ID: 30855996
    [No Abstract]   [Full Text] [Related]  

  • 16. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.
    Furtado RHM; Bonaca MP; Raz I; Zelniker TA; Mosenzon O; Cahn A; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Ruff CT; Nicolau JC; Gause-Nilsson IAM; Fredriksson M; Langkilde AM; Sabatine MS; Wiviott SD
    Circulation; 2019 May; 139(22):2516-2527. PubMed ID: 30882239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical Considerations for the Use of Sodium-Glucose Co-Transporter 2 Inhibitors in Heart Failure.
    Honigberg MC; Vardeny O; Vaduganathan M
    Circ Heart Fail; 2020 Feb; 13(2):e006623. PubMed ID: 32059632
    [No Abstract]   [Full Text] [Related]  

  • 18. Reduced hospitalization for heart failure using anti-diabetic drug dapagliflozin: implications of DECLARE-TIMI 58 for the basic science community.
    Kondo H; Takahashi N
    Cardiovasc Res; 2019 May; 115(6):e54-e57. PubMed ID: 31077584
    [No Abstract]   [Full Text] [Related]  

  • 19. Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure.
    Tanaka H; Soga F; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI
    Cardiovasc Diabetol; 2020 Jan; 19(1):6. PubMed ID: 31910853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute heart failure, type 2 diabetes and loop diuretic use: any adjunct role for sodium-glucose cotransporter-2 inhibitors?
    Patoulias D; Papadopoulos C; Zografou I; Doumas M
    J Cardiovasc Med (Hagerstown); 2020 Apr; 21(4):343. PubMed ID: 31977537
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.